MedTrace Logo

A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China

NCT06082986 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-06-26

No results posted yet for this study

Summary

Bio-naive participants are defined as the participants who previously have not received any biologics for Crohn's Disease (CD).The purpose of this retrospective study is to describe the endoscopic remission at week 24 among bio-naive participants with CD treated with ustekinumab in China.

Conditions

  • Crohn Disease

Interventions

DRUG

Ustekinumab

No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.

Sponsors & Collaborators

  • Xian-Janssen Pharmaceutical Ltd.

    lead INDUSTRY

Principal Investigators

  • Xian-Janssen Pharmaceutical Ltd., China Clinical Trial · Xian-Janssen Pharmaceutical Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-09
Primary Completion
2024-06-05
Completion
2024-06-05

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06082986 on ClinicalTrials.gov